Dinah Weismann
Company: Alcediag
Job title: Chief Executive Officer & Chief Scientific Officer
Seminars:
Panel Discussion: The Future Possibilities of RNA Editing 4:40 pm
day: Day Two
RNA Editing for Personalized Diagnostics in Neuropsychiatry 1:00 pm
Exploring how Alcediag develops RNA editing blood biomarkers powered by artificial intelligence in Mental health and neurosciences, inflammatory disease and oncology Discovering EDIT-B, EDIT-B is the first blood test based on RNA editing biomarkers to be introduced in psychiatry where diagnoses are only based on clinical evaluations Highlighting the efficacy of EDIT-B, it differentiates unipolar…Read more
day: Day Two